ID | 61458 |
FullText URL | |
Author |
Ikeda, Tomoka
Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Gion, Yuka
Division of Pathophysiology, Okayama University Graduate School of Health Sciences
Kaken ID
researchmap
Nishimura, Yoshito
Department of General Medicine, Okayama University Hospital
ORCID
publons
researchmap
Nishimura, Midori Filiz
Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Yoshino, Tadashi
Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kaken ID
publons
researchmap
Sato, Yasuharu
Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
ORCID
Kaken ID
researchmap
|
Abstract | Epstein-Barr virus (EBV)-positive mucocutaneous ulcer (EBVMCU) was first described as a lymphoproliferative disorder in 2010. EBVMCU is a unifocal mucosal or cutaneous ulcer that often occurs after local trauma in patients with immunosuppression; the patients generally have a good prognosis. It is histologically characterized by proliferating EBV-positive atypical B cells accompanied by ulcers. On the basis of conventional pathologic criteria, EBVMCU may be misdiagnosed as EBV-positive diffuse large B-cell lymphoma or other lymphomas. However, its prognosis differs from that of EBV-associated lymphomas, in that patients with EBVMCU frequently show spontaneous regression or complete remission without chemotherapy. Therefore, EBVMCU is now recognized as a low-grade malignancy or a pseudo-malignant lesion. Avoiding unnecessary chemotherapy by distinguishing EBVMCU from other EBV-associated lymphomas will reduce the burden and unnecessary harm on patients. On the basis of these facts, EBVMCU was first described as a new clinicopathological entity by the World Health Organization in 2017. In this review, we discuss the clinicopathological characteristics of previously reported EBVMCU cases, while focusing on up-to-date clinical, pathological, and genetic aspects.
|
Keywords | EBV-positive mucocutaneous ulcer
clinical features
pathological features
immunosuppression
|
Published Date | 2021-01-21
|
Publication Title |
International Journal of Molecular Sciences
|
Volume | volume22
|
Issue | issue3
|
Publisher | MDPI
|
Start Page | 1053
|
ISSN | 1422-0067
|
NCID | AA12038549
|
Content Type |
Journal Article
|
language |
English
|
OAI-PMH Set |
岡山大学
|
Copyright Holders | © 2021 by the authors.
|
File Version | publisher
|
PubMed ID | |
DOI | |
Web of Science KeyUT | |
Related Url | isVersionOf https://doi.org/10.3390/ijms22031053
|
License | http://creativecommons.org/licenses/by/4.0/
|
Funder Name |
Japan Society for the Promotion of Science
|
助成番号 | 19K16586
JP 20K07407
|